Collaboration with Sanofi - Presented at AACR Annual Meeting 2019
Despite the success of checkpoint blockade immunotherapy, most patients do not respond adequately to treatment and tumors effectively evade T lymphocyte and Natural Killer (NK) cell immune surveillance. Within the tumor microenvironment, the activities of immune cells are regulated by a multitude of signals, including the local cytokine milieu. Intratumoral administration of our cytokine mRNA cocktail therapy, consisting of transcripts encoding for IL-12sc, IFNα, IL-15sushi and GM-CSF, has induced regression in tumor-bearing mice. Leveraging in vitro, in vivo, and in silico data, we have developed a QSP platform that captures the observed preclinical tumor responses and allows for systemic predictions under a variety of conditions.